Not Yet Recruiting OBSERVATIONAL NCT06802848

Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)

Effectiveness and Safety of Xeligekimab in Adult Patients With Moderate to Severe Plaque Psoriasis: A Multicenter, Prospective, Real-World Study

Sponsor: Chongqing Genrix Biopharmaceutical Co., Ltd

Conditions Genital Psoriasis Nail Psoriasis Palmoplantar Psoriasis Plaque Psoriasis Psoriatic Arthritis Scalp Psoriasis

Interventions Xeligekimab injection

Updated 2 times since 2025 Last updated: Jan 26, 2025 Started: Jan 30, 2025 Primary completion: Mar 31, 2026 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Genital Psoriasis and Nail Psoriasis and is currently actively recruiting participants. Chongqing Genrix Biopharmaceutical Co., Ltd leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

2 versions recorded

Jun 2025 — Present [monthly]

Not Yet Recruiting
Feb 2025 — Jun 2025 [monthly]

Not Yet Recruiting

First recorded

Jan 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chongqing Genrix Biopharmaceutical Co., Ltd
Xiangya Hospital of Central South University

Data source: Chongqing Genrix Biopharmaceutical Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hunan, China